Aquestive Therapeutics announces common stock offering, no amount given

Aquestive Therapeutics announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the securities in the public offering are being offered by Aquestive. Aquestive intends to use the net proceeds of this offering, together with the company’s existing cash and cash equivalents, primarily to advance the development and commercialization of its product pipeline, including Anaphylm Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, and Libervant Buccal Film for the treatment of seizure clusters in epilepsy patients aged two to five, and for working capital, capital expenditures and general corporate purposes. Leerink Partners and Piper Sandler are acting as joint bookrunning managers for this offering. Oppenheimer & Co. is acting as lead manager for this offering.